Prevention

Latest News

Uninterrupted Anticoagulation With Dabigatran Improves Atrial Fibrillation Ablation Outcomes, Expert Q&A

Uninterrupted Anticoagulation With Dabigatran Improves Atrial Fibrillation Ablation Outcomes, Expert Q&A

Incidence of major bleeding events was lower with dabigatran vs warfarin in atrial fibrillation ablation.

Analyzing Patient Heterogeneity Upon Antihypertensive Therapy Initiation to Personalize Prognosis

Analyzing Patient Heterogeneity Upon Antihypertensive Therapy Initiation to Personalize Prognosis

Patients with higher baseline blood pressure had higher 6-month combined cardiovascular disease incidence after adjustments.

Higher BMI Linked With Lower Mortality in Adult Congenital Heart Disease

Higher BMI Linked With Lower Mortality in Adult Congenital Heart Disease

Higher BMI was associated with lower all-cause and cardiac mortality in adults with congenital heart disease, even after adjusting for age, defect complexity, cyanosis, and objective exercise capacity.

HIV Infection Associated With Elevated Cardiovascular Disease Risk

HIV Infection Associated With Elevated Cardiovascular Disease Risk

Those with HIV infection experience an elevated risk for CVD, potentially exacerbated by the use of certain antiretroviral therapies.

Cardiometabolic Risk Increased With Maternal Hyperglycemia In Pregnancy

Cardiometabolic Risk Increased With Maternal Hyperglycemia In Pregnancy

Children whose mothers had gestational diabetes were more likely to be overweight or obese or have elevated BMI, blood pressure, or abnormal glucose tolerance.

Evaluating Cangrelor Vs Clopidogrel In Percutaneous Coronary Intervention

Evaluating Cangrelor Vs Clopidogrel In Percutaneous Coronary Intervention

Researchers studied the safety and efficacy of cangrelor in patients receiving unfractionated heparin for PCI.

Statin Eligibility Requirements In African Americans With Atherosclerosis

Statin Eligibility Requirements In African Americans With Atherosclerosis

According to ACC/AHA Guidelines presented at ACC 2017, targeted imaging should be used to personalize statin recommendation programs.

Cognition Not Adversely Affected by Evolocumab With Statin Therapy

Cognition Not Adversely Affected by Evolocumab With Statin Therapy

No differences were seen in measures of executive function between the evolocumab and placebo groups.

LDL-C Lowered Below Current Targets Beneficial to Atherosclerotic CVD

LDL-C Lowered Below Current Targets Beneficial to Atherosclerotic CVD

Evolocumab reduced LDL-C levels by 59% and lowered the risk of CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15%.

Bococizumab Reduced Cardiovascular Events in High-Risk But Not Low-Risk Patients

Bococizumab Reduced Cardiovascular Events in High-Risk But Not Low-Risk Patients

In the combined SPIRE trials, the mean change in LDL-C levels was −56.0% in the bococizumab group and +2.9% in the placebo group.

Sign Up for Free e-Newsletters